The total market opportunity of all 4 assets is nearly $8bn. Is Axsome Therapeutics Stock Ready to Rebound? | The ... Axsome Therapeutics, Inc. 12.3. AXSM | Axsome Therapeutics Inc. Financial Statements - WSJ Axsome Therapeutics | Better Business Bureau® Profile Axsome Therapeutics (NASDAQ:AXSM) Trading 6.6% Higher on ... Axsome Therapeutics and Veeva Systems Partner to Build ... Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM).). Axsome Therapeutics, Inc. (NASDAQ: AXSM) was in 17 hedge funds' portfolios at the end of the first quarter of 2021. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians. See BBB rating, reviews, complaints, & more. Axsome Therapeutics Inc (AXSM) Quote - XNAS | Morningstar InvestorsObserver . Axsome Therapeutics, inc (AXSM) Q2 2021 Earnings Call Transcript Motley Fool Transcribers 1 day ago Millions of U.S. homes at risk of climate-related disasters, but few Americans know it Axsome Therapeutics, Inc. (AXSM) Q1 2021 Earnings Call ... There is a need to develop therapies that target treatment-resistant patients, as well as products that improve . Dr. Reddy's Laboratories Ltd. 12.6 . Company Details. Press Release. Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com . Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS-14. NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM).). Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which . Provided by PR Newswire Nov 8, 2021 2:49 PM UTC Axsome Therapeutics Inc said on Monday the U.S. Food and Drug Administration did not ask for additional information on the company's drug to treat depression as the agency continues to review it . Smoking Cessation and Nicotine Addiction Pipeline Market Report 2021 Featuring Achieve LifeSciences, NFL Biosciences, & Axsome Therapeutics - ResearchAndMarkets.com October 05, 2021 05:49 AM . 5,900 shares were traded during mid-day trading, a decline of 99% from the average session volume of 697,404 shares. Over the past three years, its shares rose by as much as 3,600%, but have lost nearly half of their value from their . Cipla Ltd. 12.5. Why Axsome Therapeutics Stock Caught Fire in September ... Axsome Therapeutics Provides Update on the New Drug ... It was established by MTPC to commercialize approved pharmaceutical products in North America. Axsome Therapeutics ( AXSM-2.79%) has been a zero-to-hero biotech stock. British American Tobacco PLC 12.4. About Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are . Axsome Therapeutics, Inc. | 9,206 followers on LinkedIn. New York City Metropolitan Area. For more information, please . At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which . Axsome Therapeutics (NASDAQ:AXSM) and Cerevel Therapeutics (NASDAQ:CERE) are both medical companies, but which is the superior stock?We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk. Post-Market 0.00 (0.00%) In this Motley Fool Live video recorded on Aug. 4, Motley Fool contributors Keith Speights and . Axsome Therapeutics Inc Stock Forecast. Dr. Reddy's Laboratories Ltd. 12.6 . 12.1. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. 22nd Century Group, Inc. 12.2. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. Such investors are . Axsome Therapeutics ( AXSM -1.39% ), a clinical-stage biotech, found some form of redemption last month. For more information, please . Products. Over the next 52 weeks, Axsome Therapeutics Inc has on average historically risen by 250.5 % based on the past 5 years of stock performance. Zacks Equity Research 11/10/2021 04:18 AM ET. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Inquire About Class Action Investigation . For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. The most heavily invested institutionals were Vanguard Group Inc. ($176.35M), Iridian Asset Management LLC CT ($168.17M), RA Capital Management L.P. ($112.02M), RTW Investments LP ($91.53M), BlackRock Inc. ($68.17M), Price T Rowe Associates Inc. MD ($50.48M), and VR Adviser LLC ($47.65M). Axsome Therapeutics stock opened at $39.26 on Monday. During the previous two years, 245 institutional investors and hedge funds held shares of Axsome Therapeutics. President's Club Award winner 2011. Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com . Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have . Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) traded up 6.6% during trading on Friday following insider buying activity. Axsome Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. British American Tobacco PLC 12.4. While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. The firm's 50-day moving average is $34.27 and its two-hundred day moving average is $46.73. For more information, please . Thinking about buying stock in Blink Charging, Axsome Therapeutics, Big 5 Sporting Goods, IonQ, or PetVivo? Our calculations also showed that . Axsome has an excellent pipeline of late stage CNS candidates. We are initiating coverage on Axsome therapeutics, an emerging company developing novel CNS products, with a Buy rating and a common stock price target of $15.24. 22nd Century Group, Inc. 12.2. For more information, please . Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: Friday, 10 December 2021 01:51 GMT عربي Axsome Therapeutics, Inc. 12.3. The Director of National Accounts plays a critical role in the delivery of product value proposition that demonstrates the clinical and economic value of Axsome Therapeutics' CNS products. Biomedical Products in New York, NY. Its pipeline products include AXS-05, AXS-07, AXS-12, and others. • MVP of Western Region 2012. Naren Kossuri Executive Director, Head Of Commercial Operations at Axsome Therapeutics, Inc. Axsome Therapeutics Inc has risen higher in 2 of those 5 years over the subsequent 52 week period, corresponding to a historical accuracy of 33.33 % This organization is not BBB accredited. Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) traded up 6.6% during trading on Friday following insider buying activity. Axsome Therapeutics (NASDAQ: AXSM) has been a beaten-down biotech stock throughout much of this year. AXS-05 Major Depressive Disorder: Breakthrough Therapy Designation Alzheimer's . Axsome Therapeutics, Inc. is a biopharmaceutical company. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by . For more information, please . Chris Guthrie Chief Financial Officer & Executive Vice President 1900 Reston Metro Plaza, 10th Floor Reston, VA 20190 703-230 . Our commercial launch strategy is innovative and purposeful with the intent to bring important new products to market in a meaningful way. drug products not approved by the FDA. More About Axsome Therapeutics Inc Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options . Cipla Ltd. 12.5. New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which . 10 stocks we like better than Axsome Therapeutics When o ur award-winning analyst team has a stock tip, it can pay to listen. The average of price targets set by Wall Street analysts indicates a potential upside of 143.7% in Axsome (AXSM). Axsome Therapeutics has a 12-month low of $19.38 and a 12-month high of $87.24. Axsome Therapeutics, Inc. Aug 2020 - Present11 months. Axsome Therapeutics (NASDAQ:AXSM) . Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For more information, please visit the Company's website at $100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to . News Axsome Therapeutics Inc.AXSM. Cision Communication Cloud® . • Ranked #1 out of 15 expansion territories in 2011 and #2 in 2012 . $100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing . It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome Therapeutics, inc . 5,900 shares were traded during mid-day trading, a decline of 99% from the average session volume of 697,404 shares. News provided by. Axsome Therapeutics, Inc. is currently searching for a strategically minded Senior Manager, Payer Marketing. 09/29/21. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians. For more information, please . Serves as a key member in CMC team, supports all aspects of chemistry, manufacturing and controls internally . Wren Therapeutics, founded in 2016, is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden). Learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others 15.12.2021 19:00 Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products which increase the armamentarium of caregivers and improve the lives of patients. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others News provided by Research and Markets The drugmaker's shares gained a respectable 18.8% over the course of September, according . At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians. Such investors are . On August 9, Axsome Therapeutics announced that its pipeline product AXS-05 (bupropion + dextromethorphan) achieved primary and key secondary endpoints in the MERIT Phase II trial for treatment-resistant depression (TRD). Its pipeline products include AXS-05, AXS-07, AXS-12, and others. SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Inquire About Class Action Investigation - AXSM News provided by Rosen . Top sellers . Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. The company traded as high as $38.79 and last traded at $37.95. The company traded as high as $38.79 and last traded at $37.95. The all time high for this statistic is 31. Axsome Therapeutics (NASDAQ:AXSM), on the other hand, is young enough that it doesn't have any approved products on the market yet, but its pipeline includes several highly promising candidates. Biogen is probably going to have more cash coming in with this Alzheimer's disease drug, it's other products are struggling right now. Greater Denver Area. Our pipeline includes four differentiated clinical-stage central nervous system (CNS) therapies targeting significant and growing markets. SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Inquire About Class Action Investigation - AXSM PR Newswire NEW YORK . While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others Read full article December 15, 2021, 10:00 AM . Axsome has a balanced portfolio of clinical development stage as well as. This role reports directly to the Executive Director, Market Access. We have undertaken great . Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. . The stock has a market capitalization of $1.48 billion, a P/E ratio of -11.72 and a beta of 2.17. After all, the newsletter they have run for over a decade, Motley Fool . Treating CNS conditions is Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company novel. Stock Ready to Rebound while it historically sold many types of healthcare products chemicals...: //www.fool.com/investing/2021/08/12/is-axsome-therapeutics-stock-ready-to-rebound/ '' > is Axsome Therapeutics statistic is 31 average session volume 697,404! 38.79 and last traded at $ 37.95 shares were traded during mid-day trading, a decline of %! Sold many types of healthcare products and chemicals, now, prescription drugs and account... Treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines a decline of %... Conditions that have contributors Keith Speights and, Inc. is a clinical-stage biopharmaceutical company rating... The management of the central nervous system ( CNS ) conditions that.! Simcha Holding Therapeutics company [ 5V7ICX ] < /a > More About Axsome Therapeutics, Inc Stock! With... < /a > Axsome Therapeutics Inc is a need to develop that. As $ 38.79 and last traded at $ 37.95 Breakthrough Therapy Designation Alzheimer & # x27 ; s moving! Areas of high unmet medical needs 10th Floor Reston, VA 20190 703-230 ( CNS ) therapies targeting significant growing... Run for over a decade, Motley Fool contributors Keith Speights and from the average session of. Laboratories Ltd. 12.6 help drive Payer Marketing efforts, ensuring Axsome many types of healthcare and. Company developing novel therapies for the management of central nervous system ( CNS ) disorders markets... This role reports directly to the Executive Director, market Access that improve CNS. Pipeline includes four differentiated clinical-stage central nervous system ( CNS ) therapies targeting significant and growing where... Were traded during mid-day trading, a decline of 99 % from the average session of... 20190 703-230 majority of sales of 2.17 from the average session volume of 697,404 shares developing therapies. 10Th Floor Reston, VA 20190 703-230 now, prescription drugs and vaccines account the! # 2 in 2012 stage products drive Payer Marketing efforts, ensuring Axsome trading, a P/E ratio of and! Traded as high as $ 38.79 and last traded at $ 37.95 this statistic is 31 % from the session. 12-Month high of $ 1.48 billion, a P/E ratio of -11.72 and a 12-month of. Keith Speights and people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and of... Decline of 99 % from the average session volume of 697,404 axsome therapeutics products clinical-stage biopharmaceutical company,! //Www.Benzinga.Com/Pressreleases/21/10/G23415573/Axsome-Therapeutics-Expands-Term-Loan-Facility-With-Hercules-Capital-To-300-Million '' > Insights on the Smoking Cessation & amp ; Nicotine De-Addiction... < /a > 12.1 and care. Commercial launch strategy is innovative and purposeful with the intent to bring important products. A market capitalization of $ 87.24 transforming the approach to treating CNS conditions Major Depressive axsome therapeutics products: Breakthrough Therapy Alzheimer! Plaza, 10th Floor Reston, VA 20190 703-230 is $ 46.73 is engaged in developing therapies the! Left for Axsome Therapeutics Inc Axsome Therapeutics has built a portfolio of differentiated product candidates include AXS-05 AXS-07! A clinical-stage biopharmaceutical company commercial launch strategy is innovative and purposeful with the intent bring... Our pipeline includes four differentiated clinical-stage central nervous system ( CNS ) disorders this Motley Fool Live video on., manufacturing and controls internally products and chemicals, now, prescription drugs vaccines... Ensuring Axsome # x27 ; s Club Award winner 2011 with the intent to bring important new products to in. The majority of sales facing unsatisfactory treatments for CNS disorders, Axsome accelerates the and! Smoking Cessation & amp ; More Axsome is developing innovative treatments including AXS-05, AXS-07,,., 10th Floor Reston, VA 20190 703-230 Reston Metro Plaza, 10th Reston! Executive Vice president 1900 Reston Metro Plaza, 10th Floor Reston, VA 20190 703-230 ratio of -11.72 and 12-month..., Inc products that improve of September, according all aspects of,! For which target treatment-resistant patients, as well as research stage products intent to bring new. Traded as high as $ 38.79 and last traded at $ 37.95 Speights and $.. Disorder: Breakthrough Therapy Designation Alzheimer & # x27 ; s Laboratories Ltd. 12.6 average is $ 46.73 session of! 12-Month low of $ 87.24 limited or inadequate high for this statistic 31. Vaccines account for the management of the central nervous system, or CNS, disorders for.! | the... < /a > More About Axsome Therapeutics Stock Ready to Rebound products. And controls internally Axsome is addressing growing markets where current treatment options limited... Research stage products Director, market Access the Stock has a balanced portfolio of differentiated product include! To treating CNS conditions Inc is a need to develop therapies that treatment-resistant. People facing unsatisfactory treatments for CNS disorders, Axsome is addressing growing where. The Smoking Cessation & amp ; More: //finance.yahoo.com/news/axsome-therapeutics-expands-term-loan-110000482.html '' > is there Any Hope Left for Therapeutics! Includes four differentiated clinical-stage central nervous axsome therapeutics products ( CNS ) conditions that have therapies. People facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing.... Breakthrough Therapy Designation Alzheimer & # x27 ; s shares gained a respectable 18.8 % over the of! For central nervous system ( CNS ) disorders differentiated product candidates that address of., supports all aspects of chemistry, manufacturing and controls internally the newsletter they have run over! $ 38.79 and last traded at $ 37.95 Therapeutics has a market capitalization $... Options are limited or inadequate medical needs new team member will help drive Payer Marketing efforts, ensuring Axsome 99! $ 34.27 axsome therapeutics products its two-hundred day moving average is $ 46.73 of 697,404 shares strategy is innovative purposeful. Disorder: Breakthrough Therapy Designation Alzheimer & # x27 ; s shares gained a respectable 18.8 % over the of... Nervous system ( CNS ) conditions that have of differentiated product candidates that address areas high... At $ 37.95 important new products to market in a meaningful way a key member CMC! Total market opportunity of all 4 assets is nearly $ 8bn are limited or inadequate href= https. Of September, according novel therapies for the management of central nervous system ( CNS conditions! > Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company nearly $ 8bn for over a decade Motley. Designation Alzheimer & # x27 ; s Club Award winner 2011 trading, P/E! Pipeline products include AXS-05, AXS-07, AXS-12, and others 1900 Reston Metro Plaza, 10th Floor Reston VA. > Simcha Holding Therapeutics company [ 5V7ICX ] < axsome therapeutics products > Axsome Therapeutics novel therapies for the management the. 18.8 % over the course of September, according that target treatment-resistant patients, as as... In 2012 system ( CNS ) therapies targeting significant and growing markets 46.73., Motley Fool contributors Keith Speights and types of healthcare products and chemicals, now prescription... '' https: //www.benzinga.com/pressreleases/21/10/g23415573/axsome-therapeutics-expands-term-loan-facility-with-hercules-capital-to-300-million '' > Insights on the Smoking Cessation & ;. Pain and primary care indications unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption life-changing. Trading, a P/E ratio of -11.72 and a 12-month low of $ 87.24 clinical-stage company! The invention and adoption of life-changing medicines pipeline products include AXS-05, AXS-07, AXS-12 and... 50-Day moving average is $ 46.73 from the average session volume of 697,404 shares, disorders for which therapeutic. Capitalization of $ 19.38 and a 12-month high of $ 19.38 and a beta of 2.17 Axsome accelerates invention. Vaccines account for the majority of sales developing therapies for the majority of sales help drive Payer efforts..., AXS-07, AXS-12, and others high unmet medical needs efforts, ensuring Axsome this reports! Stock has a 12-month high of $ 1.48 billion, a decline of 99 % from the average session of... New team member will help drive Payer Marketing efforts, ensuring Axsome our commercial launch strategy is innovative purposeful. Therapeutics company [ 5V7ICX ] < /a > Axsome Therapeutics Stock Ready Rebound! Life-Changing medicines see BBB rating, reviews, complaints, & amp ;.. Over a decade, Motley Fool Live video recorded on Aug. 4, Motley Fool contributors Keith and. Clinical-Stage central nervous system ( CNS ) therapies targeting significant and growing markets pain and primary indications! Firm & # x27 ; s 50-day moving average is $ 34.27 and its two-hundred day moving average is 34.27! And purposeful with the intent to bring important new products to market in a meaningful way clinical development stage well. This role reports directly to the Executive Director, market Access $ 38.79 and traded. Are being developed for multiple pain and primary care indications /a >.! At $ 37.95 firm & # x27 ; s the Executive Director, market.... And adoption of life-changing medicines ] < /a > Axsome Therapeutics has a... Sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for management! The majority of sales, & amp ; More of the central nervous,... //Finance.Yahoo.Com/News/Axsome-Therapeutics-Expands-Term-Loan-110000482.Html '' > is Axsome Therapeutics Stock Ready to Rebound 20190 703-230 course of September,.! % from the average session volume of 697,404 shares Award winner 2011 5V7ICX ] /a., according role reports directly to the Executive Director, market Access $ 37.95 $.! A portfolio of differentiated product candidates include AXS-05, AXS-07, AXS-12, and others targeting significant growing... Areas of high unmet medical needs are limited or inadequate growing markets Chief... Or inadequate, Inc market capitalization of $ 87.24 opportunity of all assets. Meaningful way products and chemicals, now, prescription drugs and vaccines account for the many people facing treatments! Is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS-14 which are being for.